Multiple myeloma (MM) remains an incurable blood cancer, but recent advancements in treatment have significantly improved patient prognosis and quality of life. UK-based specialist diagnostic company The Binding Site has developed a new strategy that monitors pre-cancerous conditions associated with MM as well as treatment success, helping to guide therapeutic pathways with more accurate information.
Ralf Griebel, Head of the Partnering Business Division
Tecan is collaborating with Luminex® Corporation to develop an innovative, automated newborn screening solution designed to rapidly identify potential health issues in infants. Luminex’s Luminex 200™ instrument with xMAP® technology is being integrated with Tecan’s Freedom EVO® liquid handling platform and HydroFlex™ washer to create the 996x™.
Tecan and FortéBio have worked together to integrate the new FortéBio Octet® 384 platform on the Freedom EVO® workstation for automated real-time, label-free assays to support bioprocessing and drug discovery workflows. Tecan has collaborated with FortéBio to deliver a robust, off-the-shelf integration that allows the user to get the most out of the Octet 384, allowing increased walkaway time as well as optional liquid handling for assay plate set-up.